SAVA,Cassava Sciences, Inc. | Healthcare

Healthcare

SAVA

All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities

Cassava Sciences, Inc.SAVA

USD

- At close

USD

- Until the end

The complete list of US stocks

MAX

Overview >

% Change

Description >

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases.

Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.

The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019.

The company was incorporated in 1998 and is based in Austin, Texas.

Latest News >

Antero Resources Insider Sold Shares Worth $1,004,472, According to a Recent SEC Filing

May 26, 2025

05:25 PM EDT, 05/19/2025 (MT Newswires) -- Yvette K Schultz, Senior Vice President, Legal, Chief Compliance Officer, General Counsel and Corporate Secretary, on May 16, 2025, sold 25,200 shares in Antero Resources ( AR ) for $1,004,472. Following the Form 4 filing with the SEC, Schultz has control over a total of 306,819 common shares of the company, with 306,819...

Family Dollar Appoints Duncan MacNaughton as Chairman and CEO

May 26, 2025

05:18 PM EDT, 05/19/2025 (MT Newswires) -- Dollar Tree ( DLTR ) announced late Monday, in partnership with Brigade Capital Management and Macellum Capital Management, that Duncan MacNaughton will serve as chairman and chief executive officer of Family Dollar. MacNaughton will lead Family Dollar after the previously announced divestiture, which is expected to close in Q2, according to a statement....

Orion Group Holdings Insider Sold Shares Worth $259,989, According to a Recent SEC Filing

May 26, 2025

05:15 PM EDT, 05/19/2025 (MT Newswires) -- Austin J Shanfelter, Director, on May 15, 2025, sold 30,000 shares in Orion Group Holdings ( ORN ) for $259,989. Following the Form 4 filing with the SEC, Shanfelter has control over a total of 419,215 common shares of the company, with 419,215 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1402829/000141588925013653/xslF345X05/form4-05192025_050501.xml ...

CRISPR, Sirius Collaborate on RNA Therapy Targeting Blood Clot Disorders

May 26, 2025

05:19 PM EDT, 05/19/2025 (MT Newswires) -- CRISPR Therapeutics ( CRSP ) and Sirius Therapeutics have entered a collaboration to develop small interfering RNA-based treatments, starting with SRSD107, a Factor XI-targeting therapy for thromboembolic conditions, the companies said late Monday. Under the agreement, CRISPR will provide $25 million in cash and $70 million in equity to Sirius upfront. The companies...